Midgley, R., Love, S., Potter, V., Segelov, E., Ferry, D. R., Weaver, A., Scudder, C., Julier, P., Grumett, S., & Kerr, D. (2016). CAPECITABINE (CAPE) +/- BEVACIZUMAB (BEV) IN THE ADJUVANT TREATMENT OF COLORECTAL CANCER (CRC) FIRST AND FINAL TOXICITY RESULTS FROM THE INTERNATIONAL PHASE III QUASAR2 TRIAL. 23, 181–182.

Midgley, R., et al. CAPECITABINE (CAPE) +/- BEVACIZUMAB (BEV) IN THE ADJUVANT TREATMENT OF COLORECTAL CANCER (CRC) FIRST AND FINAL TOXICITY RESULTS FROM THE INTERNATIONAL PHASE III QUASAR2 TRIAL. 2016, pp. 181–82.

Midgley, R, S Love, V Potter, E Segelov, DR Ferry, A Weaver, C Scudder, P Julier, S Grumett, and D Kerr. 2016. “CAPECITABINE (CAPE) +/- BEVACIZUMAB (BEV) IN THE ADJUVANT TREATMENT OF COLORECTAL CANCER (CRC) FIRST AND FINAL TOXICITY RESULTS FROM THE INTERNATIONAL PHASE III QUASAR2 TRIAL.” In , 23:181–82.